Guggenheim Raises Relay Therapeutics Target to $26 on RLY-2608 Data
0h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
relay-therapeuticsbiotech-stocks
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Guggenheim Partners issued a research note on 26 May 2026 raising its price target for Relay Therapeutics, Inc. (RGTX) to $26 from a previous level. The adjustment reflects increased analyst conviction in the commercial potential of RGTX's lead drug candidate, RLY-2608, a next-generation PI3Kα inhibitor for treating certain breast cancers. Relay Therapeutics stock was trading at $12.60, up 2.67% on the day, with shares reaching an intraday high of $12.80. The new target implies a potential upside of over 100% from current levels, signaling a significant re-rating based on the drug's clinical profile.
Oncology drug development faces intense competition, making differentiated mechanisms of action critical for commercial success. The PI3K pathway is a well-validated target in cancer, but earlier-generation inhibitors have been hampered by toxicity issues limiting their use. RLY-2608 is designed as a mutant-selective PI3Kα inhibitor, aiming to deliver efficacy while minimizing the adverse events that plagued previous drugs in the class. The timing of Guggenheim's update is tied to the maturation of early clinical data, which has begun to demonstrate this improved therapeutic window.
The broader biotech sector is also showing signs of renewed investor interest in high-risk, high-reward clinical-stage assets. After a prolonged period of risk aversion and tight funding, positive clinical readouts are being met with more substantial market reactions. This shift creates a favorable backdrop for companies like Relay Therapeutics that are approaching key inflection points. The need for novel treatments in HR+/HER2- breast cancer, a large market segment, provides a clear commercial pathway for successful drugs.
Guggenheim's new price target of $26 represents a substantial increase and projects a 107% gain from RGTX's current price of $12.60. The stock's trading range on the day of the announcement was $12.51 to $12.80, reflecting heightened volatility around the news. Relay Therapeutics' market capitalization stands at approximately $1.6 billion, a valuation that heavily discounts the future revenue potential of its pipeline.
For context, the performance of RGTX contrasts with the broader market. While Relay Therapeutics surged 2.67% on the day, the SPDR S&P Biotech ETF (XBI) was relatively flat. This outperformance highlights the stock-specific nature of the catalyst. The price target revision is one of the most bullish among covering analysts, with the consensus price target likely to move higher from its pre-announcement level.
| Metric | Before Announcement | After Announcement |
|---|---|---|
| Guggenheim Price Target | Previous Target | $26 |
| Implied Upside from $12.60 | --- | 107% |
The positive development for Relay Therapeutics has implications for the broader oncology-focused biotech sector. Success for a mutant-selective PI3Kα inhibitor validates a targeted approach to overcoming historical toxicity challenges. Peers developing next-generation kinase inhibitors, such as companies in the `KRAS` or `EGFR` inhibitor space, may see increased investor interest as the market rewards improved safety profiles. Conversely, developers of older PI3K inhibitors may face further competitive pressure.
A key risk to the bullish thesis is the ongoing clinical development path. The data supporting the target raise is from early-stage trials; Phase 3 studies are required for regulatory approval and will be the ultimate test of the drug's efficacy and safety. Investor positioning suggests a mix of long-term believers and short-term traders capitalizing on volatility. Trading volume was elevated compared to the 30-day average, indicating significant institutional and algorithmic flow into the name.
The next major catalyst for Relay Therapeutics will be the presentation of additional clinical data from the ongoing trial of RLY-2608, expected at a major oncology conference in the fourth quarter of 2026. Investors will scrutinize updates on patient response rates and the duration of response. The company may also provide guidance on the design of a pivotal Phase 3 trial, which would outline the path to a potential New Drug Application.
Key technical levels to monitor include the stock's recent high near $12.80, which now acts as immediate resistance. A sustained break above this level could signal further momentum. On the downside, support is likely found near the 50-day moving average, around $11.50. Regulatory milestones from the U.S. Food and Drug Administration regarding the trial design will be another critical watchpoint for 2027.
A PI3Kα inhibitor is a type of targeted cancer therapy that blocks the activity of the PI3K alpha enzyme, which is often mutated and overactive in cancers like breast cancer. This enzyme is part of a signaling pathway that controls cell growth and survival. Inhibiting it can slow or stop cancer progression. RLY-2608 is significant because it is designed to target only the mutated form of the enzyme, potentially avoiding the severe side effects of earlier, less selective inhibitors.
Relay Therapeutics utilizes a distinct drug discovery platform that focuses on visualizing the dynamic movement of proteins, rather than just their static structure. This approach, which includes techniques like hydrogen-deuterium exchange, aims to identify drug candidates that can interact with proteins in novel ways. For RLY-2608, this meant designing a molecule that could selectively inhibit the cancer-driving mutant PI3Kα while sparing the normal, healthy version of the protein.
RLY-2608 targets HR+/HER2- breast cancer patients with specific PIK3CA mutations, a segment representing a multi-billion dollar global market. Current standard-of-care treatments in this setting include other targeted therapies, but toxicity often leads to dose reductions or discontinuation. A drug with comparable efficacy and a superior safety profile could capture significant market share. Peak sales estimates for successful drugs in this category can exceed $1 billion annually, which justifies the current speculative valuation of Relay Therapeutics.
Guggenheim's target hike prices in a high conviction that Relay Therapeutics' lead asset can overcome a key hurdle in oncology drug development.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.